A Study to Learn How the Study Medicine PF-07899895 Are Tolerated and Act in the Body of Healthy Adults
A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of PF-07899895 Administered as Immediate and Modified Release Formulations in Healthy Adult Participants
Sponsor: Pfizer
Terminated
Study was terminated early . This decision was not due to any safety concerns associated with PF-07899895 but rather due to a business decision.
Listed as NCT06137729, this PHASE1 trial focuses on Healthy and remains terminated or withdrawn. Sponsored by Pfizer, it has been updated 11 times since 2023, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Dec 2025 — Present [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Jul 2025 — Dec 2025 [monthly]
Recruiting PHASE1
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE1
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE1
-
Nov 2024 — May 2025 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
▶ Show 6 earlier versions
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
-
Apr 2024 — May 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2024 — Apr 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Dec 2023 — Feb 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Nov 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .